Asunto(s)
Melanoma , Neoplasias Cutáneas , Humanos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Pueblos del Este de Asia , Ipilimumab/uso terapéutico , Melanoma/tratamiento farmacológico , Melanoma/etiología , Nivolumab/uso terapéutico , Estudios Retrospectivos , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/etiologíaAsunto(s)
Pueblo Asiatico , Colitis Ulcerosa/etiología , Enfermedad de Crohn/etiología , Diverticulosis del Colon/etiología , Enfermedades del Sigmoide/etiología , Anciano , Anciano de 80 o más Años , Colitis Ulcerosa/diagnóstico , Colitis Ulcerosa/dietoterapia , Enfermedad de Crohn/diagnóstico , Enfermedad de Crohn/dietoterapia , Dieta/efectos adversos , Diverticulosis del Colon/diagnóstico , Diverticulosis del Colon/dietoterapia , Femenino , Humanos , Masculino , Enfermedades del Sigmoide/diagnóstico , Enfermedades del Sigmoide/dietoterapiaRESUMEN
Here we report two cases of primary skeletal muscle lymphoma. The first patient was an 82-year-old man. On April 2004, he was referred to our hospital because of swelling of the right upper arm. Magnetic resonance imaging (MRI) showed an area which was isointense on T1 and hyperintense on T2-weighted imaging compared with normal skeletal muscle. The size of the tumor was 5 x 7 x 13 cm. Following pathological, flow cytometric and genetic analyses of the specimen, we diagnosed the tumor as a non-Hodgkin lymphoma of the T-cell rich diffuse large B-cell type. The second patient was an 87-year-old man. He was admitted to our hospital on July 2004, under the chief complaint of swelling of the right thigh. MRI revealed a giant tumor mass of the right thigh which was isointense on T1 and hyperintense on T2 imaging. The patient was diagnosed by open biopsy as having diffuse large B-cell lymphoma. We could find only 62 cases of primary skeletal muscle lymphoma through a MEDLINE search. We report on our two cases with a review of the literature.
Asunto(s)
Linfoma de Células B/diagnóstico , Linfoma de Células B Grandes Difuso/diagnóstico , Linfoma no Hodgkin/diagnóstico , Linfoma de Células T/diagnóstico , Neoplasias de los Músculos/diagnóstico , Músculo Esquelético , Anciano de 80 o más Años , Resultado Fatal , Humanos , Linfoma de Células B/patología , Linfoma de Células B/terapia , Linfoma de Células B Grandes Difuso/patología , Linfoma de Células B Grandes Difuso/terapia , Linfoma no Hodgkin/patología , Linfoma no Hodgkin/terapia , Linfoma de Células T/patología , Linfoma de Células T/terapia , Imagen por Resonancia Magnética , Masculino , Neoplasias de los Músculos/patología , Neoplasias de los Músculos/terapia , Resultado del TratamientoAsunto(s)
Anemia Ferropénica/metabolismo , Anemia/metabolismo , Hierro/metabolismo , Anemia/etiología , Anemia Ferropénica/genética , Animales , Péptidos Catiónicos Antimicrobianos/fisiología , Proteínas de Transporte de Catión/genética , Proteínas de Transporte de Catión/fisiología , Enfermedad Crónica , Hepatitis/complicaciones , Hepcidinas , Humanos , Inflamación/complicaciones , Proteínas de Unión a Hierro/genética , Proteínas de Unión a Hierro/fisiología , Neoplasias Hepáticas/complicaciones , Sistema Mononuclear Fagocítico/metabolismo , Receptores de Transferrina/fisiología , Transferrina/genética , Transferrina/fisiologíaRESUMEN
We measured paclitaxel (PTX) concentrations in blood and ascites in a patient with advanced gastric cancer treated with weekly paclitaxel (80 mg/m2). After 180 minutes from infusion of PTX, the concentration of PTX in ascites was 13 ng/ml, which was more than the reported cytotoxic dose of PTX (8.5 ng/ml). The concentration of PTX in ascites was retained, and rose rather slowly during a 24-hour period. The patient died soon after the measurement, meaning this measurement was taken at a time when the antitumor effect was ineffective and under poor general conditions. The result suggested, however, that the desired concentration of PTX in ascites can be obtained with a smaller dose of PTX in a regimen of weekly PTX.
